Pipeline Report: July 2021 | Articles

Ficlatuzumab Plus Chemotherapy Produces Promising Preliminary Clinical Activity in High-Risk AML

July 21st 2021

The investigational therapy ficlatuzumab in combination with cytarabine demonstrated encouraging clinical efficacy with favorable tolerability when used as a treatment in patients with high-risk acute myeloid leukemia.

Leronlimab Plus Carboplatin Showcases Early Signs of OS Benefit in Metastatic TNBC

July 20th 2021

The CCR5 antagonist leronlimab plus carboplatin was shown to result in a 72% decrease in cancer-associated macrophage-like cells, which was linked with an approximate 450% increase in overall survival in 30 patients with metastatic triple-negative breast cancer.

Belapectin/Pembrolizumab Shows Early Activity, Tolerability in Metastatic Melanoma & Head and Neck Cancer

July 11th 2021

The combination of belapectin plus pembrolizumab has demonstrated early potential for disease control with acceptable tolerability in patients with metastatic melanoma and head and neck cancer.

Galinpepimut-S Plus Pembrolizumab Shows Early Activity in Advanced Ovarian Cancer

July 9th 2021

The combination of galinpepimut-S and pembrolizumab has demonstrated promising clinical immunobiological activity in patients with Wilms Tumor 1–positive, relapsed or refractory, platinum-resistant advanced metastatic ovarian cancer, according to results from an ad-hoc analysis of a phase 1/2 trial.

RNAi Therapy ARO-HIF2 Shows Early Activity, Tolerability in Heavily Pretreated Clear Cell RCC

July 7th 2021

The investigational RNA interference therapy, ARO-HIF2, was shown to have encouraging signals of activity with favorable tolerability in heavily pretreated patients with advanced clear cell renal cell carcinoma.

Rigosertib/Nivolumab Combo Shows Early Potential in KRAS-Mutated NSCLC

July 6th 2021

The novel combination comprised of rigosertib and nivolumab showed preliminary evidence of potential anticancer activity in patients with advanced metastatic KRAS-mutated non–small cell lung cancer.